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This year’s ERS International Congress was, as 
always, well-organised, providing participants 
with a good mixture of translational and clinical 
science. The emerging trend throughout the con-
ference was the personalised approach, dedicated 
to better understanding, characterising and thus 
managing patients as individuals with unique 
combinations of clinical characteristics rather 
than as a single diagnostic entity.
One hot topic discussed was the concept of co- 
morbidity networks, which is especially  important 
in chronic diseases, including chronic obstructive 
pulmonary disease (COPD), accompanied by a wide 
range of extra-pulmonary clinical  manifestations 
affecting the outcome or treatment. Targeting 
not only the disease but also its co-morbidity 
 network will be the next step towards  personalised 
 medicine. This new paradigm has led to the 
 development of the new concept of “network 
science” to better understand complex diseases by 
mapping the interconnectivity of co-morbidities.
Another important clinical item, which is also 
highly relevant in terms of epidemiology, was 
the overlap between COPD, asthma and cancer. 
While the overlap between COPD and cancer has 
 previously been acknowledged, asthma–COPD 
overlap syndrome (ACOS), is only recently gaining 
increasing attention. Although a consistent defini-
tion is still lacking, ACOS is generally defined as a 
condition with clinical features from both asthma 
and COPD. Consequently, extensive phenotyping 
should take place prior to including ACOS patients 
into clinical trials in order to clarify whether a strict 
definition will be beneficial for routine clinical 
practice. To date, clinicians assess these patients 
every day, as they probably represent 15–45% of 
the entire COPD population, but do not diagnose or 
treat them differently than pure COPD or asthma 
patients as there are no dedicated guidelines. Their 
lack is partly due to the fact that only a few stud-
ies have assessed treating these patients, as most 
COPD studies exclude nonsmokers and patients 
with some bronchodilator reversibility, whereas 
asthma studies excluded the opposite groups. 
Patients with ACOS require different management 
to patients with COPD alone but, if treated opti-
mally, have a better prognosis. This ACOS sympo-
sium exemplified the emergence of phenotypes 
and overlap syndromes in chronic airway disorders, 
highlighting the need of  large-scale studies to 
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 better understand the molecular and genetic back-
ground of airway diseases. One possible approach 
for this includes systems biology, which investi-
gates diseases at numerous end points in a very 
sophisticated and unbiased statistical manner. 
During the congress, the first results of the recently 
completed pan-European study U-BIOPRED (Unbi-
ased Biomarkers in Prediction of Respiratory Dis-
ease Outcomes) were presented. This systems 
medicine approach is also applied within the field 
of lung transplantations by means of large cohorts 
including the SysCLAD (Systems Prediction of 
Chronic Lung Allograft Dysfunction) cohort. Indeed, 
the lung transplant field embraces the awareness 
that such systems medicine studies together with 
larger patient cohorts and multicentre approaches 
are essential to obtaining solid results. A special 
recognition should go the work of David Ruttens 
who performed a first European-wide study with 
over 5000 lung transplant patients from 13 Euro-
pean lung transplant centres, which was also cov-
ered in a press release by ERS.
The importance of phenotyping and subtyping 
chronic lung diseases was further underling by the 
discussed shift in paradigm observed within the 
asthma field. Nowadays, asthma is considered a 
collection of a wide range of temporary alternating 
phenotypes. More importantly, airway inflamma-
tion is no longer an obligate component of bron-
chial asthma definition. The Global Initiative for 
Asthma (GINA) suggests maximising the under-
standing of the underlying mechanisms leading to 
asthmatic symptoms in each individual. Therefore, 
underused techniques to measure airway inflam-
mation or forced oscillation technique, which may 
be especially useful in diagnosing patients with 
poor cooperation during pulmonary function tests 
performance.
In the last few years, personalised medicine 
has also entered the field of lung transplantation, 
especially regarding phenotyping chronic lung 
allograft dysfunction (CLAD). Understanding the 
two major CLAD entities, bronchiolitis obliterans 
syndrome and restrictive allograft syndrome, and 
how to deal with them with respect to diagnosis, 
follow-up, therapy and outcome is again a major 
concern.
Besides characterisation of various clinical 
phenotypes, the influence of smoking on the 
immune mechanisms underlying different dis-
ease phenotypes was discussed. It was shown 
that the development of an emphysema–COPD 
phenotype or lung cancer in smokers depends on 
which cell types are affected. This was exempli-
fied by a process called T-cell exhaustion, which is 
characterised by stepwise and progressive loss of 
T-cell functions and can culminate in the physical 
deletion of the responding cells mainly in chronic 
inflammatory diseases as well as in tumor expan-
sion. The influence of pre- and postnatal second-
hand smoke exposure on the development of 
lung pathologies was also discussed, as evidence 
strongly links such exposure to a wide range of 
manifestations, including extra-pulmonary pathol-
ogies, in the offspring.
Latent tuberculosis (TB) infection was also high-
lighted in a “Hot Topic” symposium following the 
recent publication of the WHO guidelines [1] on 
this subject. Approximately one-third of the world’s 
population is infected with latent TB and the new 
guidelines provide a public health approach to iden-
tification and treatment of individuals with high-
est risk of progression to active disease including 
immunosuppressed patients or immigrants from 
high TB burden countries [1]. Taking into account 
the vast influx of refugees into Europe, a special 
interest was raised regarding newest develop-
ments in diagnosis and treatment of TB and multi-
drug-resistant TB. Rates of TB are thus expected to 
continue to increase as more people gain access to 
European healthcare systems.
Much interest was also generated by presenta-
tions from the EMBARC (European Bronchiectasis 
Registry) study group, a new ERS pan-European 
collaborative registry of patients with non-cystic 
fibrosis bronchiectasis [2]. Key questions that 
will be tackled by EMBARC include the role of 
Pseudomonas spp. eradication, type and duration 
of antibiotic therapy in exacerbations and iden-
tification of risk factors for disease progression. 
There is heterogeneity in bronchiectasis service 
provision within Europe at present and EMBARC 
will provide guidance for future standardisation.
As always, there was an important update on 
patients with critical conditions. High-flow oxygen 
through nasal cannula (HFONC) has been one 
of the most discussed new topics in critically ill 
patients, especially its use in the treatment of 
hypoxaemic acute respiratory failure. The FLORALI 
(High-FLow Oxygen Therapy for the Resuscitation 
of Acute Lung Injury) study, showed that HFONC 
reduced overall mortality as well as the cumula-
tive incidence of intubation in specified subset of 
patients [3]. Although some concerns were raised 
regarding the noninvasive ventilation settings 
applied in this study, its results surely created 
awareness regarding the use of noninvasive venti-
lation in hypoxaemic acute respiratory failure.
Another rising topic within the treatment of 
patients with critical conditions is the use of extra-
corporeal CO2 removal. Recently, veno–venous 
 systems with an external pump have been intro-
duced to efficiently and safely reduce endotracheal 
intubation in patients with acute chronic  respiratory 
failure.
The recent Volkswagen scandal with fraudu-
lent emission data, obtained in laboratory testing 
of the engines rather than real-life measurements 
of air-pollution, was also discussed. This has led 
to the following statement issued by the ERS 
Executive Committee: “Assessments of air pol-
lution impacts on health and ecosystems should 
be based on real-world emission data, not on val-
ues obtained in laboratory settings, which have 
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become more and more remote from the real 
world over recent years.”
There was also an excellent programme of 
sleep medicine presented. In particular the 
symposium on neurological and memory issues 
in sleep disordered breathing presented new and 
exciting advances in the field. More difficult, were 
the disappointing outcomes of the SERVE-HF trial 
which showed increased mortality in patients with 
central sleep apnoea in the context of low ejection 
fractions (<30%) using adaptive servo- ventilation 
therapy. This was an unexpected outcome  overall 
and one which will require a great deal of soul-
searching in the next few months. Something for 
all who treat sleep-disordered breathing should 
definitely be aware of!
Alongside clinical and scientific sessions, this 
year’s Congress again offered educational ses-
sions, including one that allowed live observation 
of endoscopic procedures performed by experts in 
the field of interventional endoscopy in patients 
with lung cancer, interstitial and pleural diseases 
as well as emphysema and severe asthma. This 
unique opportunity gave members with an inter-
est in this field the possibility of widening their 
knowledge and skill set.
Finally, to celebrate the benefits of exercise for 
health and wellbeing, Assembly 10 ran a com-
petition that encouraged all members to track 
their steps each day with the aim of walking more 
than 10,000 steps per conference day. Dr Klaus 
Polke managed the most steps in a single day, an 
impressive 69,011! Congratulations!
Overall, this year’s ERS International Congress 
once more has proven to be the place where science, 
clinic education and lifestyle meet. Indeed, not only 
the most recent scientific and clinical data regard-
ing disease phenotyping, treatment modalities and 
environmental risks were presented, but educating 
our respiratory experts and pursuing a healthy life-
style were proactively advocated as well. Therefore, 
we would like to invite especially those juniors who 
have never attended the ERS International Congress 
before, to join us in London next year.
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